These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 7872765)
21. Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections. Fournier JL; Ramisse F; Jacolot AC; Szatanik M; Petitjean OJ; Alonso JM; Scavizzi MR Antimicrob Agents Chemother; 1996 Feb; 40(2):325-30. PubMed ID: 8834874 [TBL] [Abstract][Full Text] [Related]
22. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Higgins PG; Wisplinghoff H; Stefanik D; Seifert H Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin. Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820 [TBL] [Abstract][Full Text] [Related]
24. Resistance to cefoperazone-sulbactam in Klebsiella pneumoniae: evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms. Rice LB; Carias LL; Etter L; Shlaes DM Antimicrob Agents Chemother; 1993 May; 37(5):1061-4. PubMed ID: 8390809 [TBL] [Abstract][Full Text] [Related]
25. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam. Piddock LJ; Jin YF; Turner HL J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105 [TBL] [Abstract][Full Text] [Related]
26. In vitro susceptibility of multi-drug resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolated from clinical specimens at Bugando Medical Centre, Tanzania to Piperacillin-Tazobactam. Petro D; Mushi MF; Moremi N; Iddi S; Mirambo M; Seni J; Mshana SE Tanzan J Health Res; 2014 Jan; 16(1):54-7. PubMed ID: 26867273 [TBL] [Abstract][Full Text] [Related]
27. Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice. Pultz MJ; Donskey CJ Antimicrob Agents Chemother; 2007 Aug; 51(8):3044-5. PubMed ID: 17562802 [No Abstract] [Full Text] [Related]
28. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Ambrose PG; Bhavnani SM; Jones RN Antimicrob Agents Chemother; 2003 May; 47(5):1643-6. PubMed ID: 12709334 [TBL] [Abstract][Full Text] [Related]
29. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro]. Zhao C; Xie W; Zhang W; Ye Z; Wu H Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663 [TBL] [Abstract][Full Text] [Related]
30. Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations. Bonfiglio G; Livermore DM J Antimicrob Chemother; 1993 Sep; 32(3):431-44. PubMed ID: 8262865 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa. Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203 [TBL] [Abstract][Full Text] [Related]
32. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Peterson LR Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544 [TBL] [Abstract][Full Text] [Related]
33. An evaluation of the in vitro activity of piperacillin/tazobactam. Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825 [TBL] [Abstract][Full Text] [Related]
34. [Efficacies of ceftazidime and cefepime in rats with experimental pneumonia caused by extended-spectrum beta-lactamase-producing strain of Klebsiella pneumonia]. Wang WF; Liu YN; She DY Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun; 29(6):390-4. PubMed ID: 17045021 [TBL] [Abstract][Full Text] [Related]
35. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. Burgess DS; Hall RG Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499 [TBL] [Abstract][Full Text] [Related]
36. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria. Appelbaum PC J Antimicrob Chemother; 1993 Jan; 31 Suppl A():29-38. PubMed ID: 8383654 [TBL] [Abstract][Full Text] [Related]